Ascletis Pharma (HKG:1672) said ASC47 the results for its new weight-loss drug, in combination with semaglutide, according to a Wednesday filing with the Hong Kong bourse.
In preclinical trials, the combination led to a 36.2% reduction in body weight in obese mice, outperforming semaglutide alone with muscle mass preserved.
The company plans further studies, with Phase II A results expected in 2025, aiming to advance obesity treatment options.
The pharmaceuticals shares were down by over 13% at day end.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。